META ANALYSIS

BACKGROUND In patients with symptomatic mitral regurgitation who are high-risk for surgery, transcatheter mitral valve repair has been shown to be safe and improve clinical outcomes. However, its impact on survival has shown con fl icting results in recent trials. METHODS PubMed, EMBASE, and Google Scholar databases were queried for all trials about MitraClip compared with optimal medical therapy RESULTS This meta-analysis of 9 trials, including 3099 patients, found that patients treated with MitraClip compared to optimal medical therapy had similar 30-day mortality (OR 0.64, 95% CI 0.32- 1.28) while at 12-months MitraClip was associated with signi fi cantly lower all-cause mortality (OR 0.50, 95% CI 0.38- 0.66). Absolute risk reduction was 13.9%, and number needed to treat to save 1 life at 12 months was 7.2. Percutaneous Mitral Valve BACKGROUND Percutaneous mitral valve (MV) repair with the MitraClip device is effective in patients with severe mitral regurgitation (MR). Patients with NYHA IV heart failure requiring inotropes or mechanical circulatory support (MCS) have been excluded from prior MitraClip studies. Co-existing renal failure is common in such pa- tients. The impact of MitraClip on renal function is not known. underwent percutaneous for or severe Renal function was assessed with serial the